MX2010006911A - Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina. - Google Patents

Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.

Info

Publication number
MX2010006911A
MX2010006911A MX2010006911A MX2010006911A MX2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A MX 2010006911 A MX2010006911 A MX 2010006911A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
dibenz0
oxepine
mineralocorticoid receptor
derived
Prior art date
Application number
MX2010006911A
Other languages
English (en)
Inventor
Prabhakar Kondaji Jadhav
Konstantinos Gavardinas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010006911(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010006911A publication Critical patent/MX2010006911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula (I); Fórmula (I) y métodos para tratar trastornos fisiológicos, particularmente falla cardiaca congestiva, hipertensión, nefropatía diabética, o enfermedad crónica renal. La presente invención se refiere a antagonistas del receptor mineralocorticoide no esteroidal.
MX2010006911A 2007-12-19 2008-12-09 Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina. MX2010006911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
MX2010006911A true MX2010006911A (es) 2010-10-05

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006911A MX2010006911A (es) 2007-12-19 2008-12-09 Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.

Country Status (34)

Country Link
US (1) US7994164B2 (es)
EP (2) EP2235007B1 (es)
JP (1) JP5562866B2 (es)
KR (1) KR101254382B1 (es)
CN (1) CN101903377B (es)
AR (1) AR069554A1 (es)
AU (1) AU2008343524B2 (es)
BR (1) BRPI0820805A2 (es)
CA (1) CA2710409C (es)
CL (1) CL2008003600A1 (es)
CO (1) CO6300953A2 (es)
DK (1) DK2235007T3 (es)
DO (1) DOP2010000185A (es)
EA (1) EA017668B1 (es)
EC (2) ECSP10010266A (es)
ES (2) ES2459318T3 (es)
GT (1) GT201000179A (es)
HK (1) HK1144284A1 (es)
HR (1) HRP20120916T1 (es)
IL (1) IL206353A (es)
MA (1) MA31910B1 (es)
MX (1) MX2010006911A (es)
MY (1) MY150474A (es)
NZ (1) NZ586300A (es)
PE (1) PE20091057A1 (es)
PL (1) PL2235007T3 (es)
PT (1) PT2235007E (es)
RS (1) RS52594B (es)
SI (1) SI2235007T1 (es)
TN (1) TN2010000292A1 (es)
TW (1) TWI431010B (es)
UA (1) UA100131C2 (es)
WO (1) WO2009085584A1 (es)
ZA (1) ZA201004257B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EA029518B1 (ru) 2014-06-30 2018-04-30 Астразенека Аб Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
BR112017007112A2 (pt) * 2014-11-21 2017-12-26 Lilly Co Eli compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JP7090599B2 (ja) * 2016-09-24 2022-06-24 山東亨利醫藥科技有限責任公司 ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
NZ532827A (en) * 2001-11-21 2007-09-28 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
US7482344B2 (en) * 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
ES2308296T3 (es) 2003-12-19 2008-12-01 Eli Lilly And Company Modulares del receptor nuclear de hormonas esteroideas triciclicas.
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008508314A (ja) 2004-07-28 2008-03-21 アイアールエム・リミテッド・ライアビリティ・カンパニー ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
KR101107800B1 (ko) 2006-10-31 2012-01-25 화이자 프로덕츠 인코포레이티드 무기질코르티코이드 수용체 길항제로서의 피라졸린 화합물
CN101652142B (zh) 2007-03-29 2013-01-02 Msd欧斯股份有限公司 盐皮质激素受体拮抗剂
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
CA2751901C (en) 2009-03-12 2013-08-06 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
HRP20120916T1 (hr) 2012-12-31
BRPI0820805A2 (pt) 2015-06-16
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
JP2011507868A (ja) 2011-03-10
IL206353A0 (en) 2010-12-30
TN2010000292A1 (en) 2011-11-11
ECSP10010266A (es) 2010-07-30
ECSP12012048A (es) 2012-08-31
AR069554A1 (es) 2010-02-03
MY150474A (en) 2014-01-30
PE20091057A1 (es) 2009-07-20
GT201000179A (es) 2012-04-16
NZ586300A (en) 2012-06-29
KR101254382B1 (ko) 2013-04-15
TWI431010B (zh) 2014-03-21
EA201070762A1 (ru) 2010-12-30
EA017668B1 (ru) 2013-02-28
PT2235007E (pt) 2013-01-22
AU2008343524A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
SI2235007T1 (sl) 2013-01-31
PL2235007T3 (pl) 2013-03-29
CA2710409C (en) 2012-11-06
DOP2010000185A (es) 2010-09-15
EP2235007B1 (en) 2012-10-31
MA31910B1 (fr) 2010-12-01
CN101903377A (zh) 2010-12-01
JP5562866B2 (ja) 2014-07-30
KR20100082866A (ko) 2010-07-20
TW200930721A (en) 2009-07-16
EP2235007A1 (en) 2010-10-06
UA100131C2 (uk) 2012-11-26
ZA201004257B (en) 2011-11-30
RS52594B (en) 2013-04-30
ES2396605T3 (es) 2013-02-22
CN101903377B (zh) 2014-07-09
CL2008003600A1 (es) 2010-02-19
AU2008343524B2 (en) 2012-03-08
EP2537845B1 (en) 2014-03-19
ES2459318T3 (es) 2014-05-09
DK2235007T3 (da) 2012-12-17
CO6300953A2 (es) 2011-07-21
IL206353A (en) 2014-06-30
HK1144284A1 (en) 2011-02-11
WO2009085584A1 (en) 2009-07-09
EP2537845A1 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
MX2010006911A (es) Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina.
UA106611C2 (uk) Інгібітори зовнішнього медулярного калієвого каналу нирок
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
MX2009005363A (es) Pirimidinas y su uso como antagonistas del receptor cxcr2.
HRP20141248T1 (en) 4-(indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as ep4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
WO2007092879A3 (en) Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
DE602005023197D1 (de) -muscarinrezeptors
WO2007109783A3 (en) Substituted pyrimidine kinase inhibitors
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
WO2007121154A3 (en) Substituted benzothiazole kinase inhibitors
UA104867C2 (uk) Похідні феноксихроманкарбонової кислоти, заміщені в 6-ому положенні
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
MX2013004739A (es) Derivados heterociclicos de diazenodiolato.
TR201818771T4 (tr) Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler
EA200801240A1 (ru) Новые способы получения производных циклопропиламида
DE602008002598D1 (en) Cyclohexylderivate
MX2013010270A (es) Derivados heterociclicos diazeniodiolato de amina primaria.
SV2009002893A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida ref. prd2560

Legal Events

Date Code Title Description
FG Grant or registration